NEW YORK (GenomeWeb) – Cordlife Group, a Singapore-based consumer healthcare company, has entered into a partnership with US company PlumCare to offer genetic testing services in Asia.
Specifically, Cordlife plans to launch the PlumCare DNA Advisor test under its Genscreen brand to help families in Asia identify gene variants associated with increased risk of developing inherited conditions such as breast and ovarian cancer.
The test combines whole-exome sequencing and analysis with clinical genetics data curation. It will be performed in CAP-accredited laboratories in the US.
The service requires participation from at least three family members to enable better counseling and insights. Adults and children will receive reports focused on the categories of cancer, cardiac, connective tissue, metabolic, and response to anesthesia; while children will also receive insights on hearing and seizures.
PlumCare was founded by Petros Tsipouras, a specialist in clinical genetics and adjunct professor at Yale University School of Medicine; and Paul Billings, a genomic medicine specialist.
Cordlife was founded in 2001 and is a leading provider of cord blood, cord tissue, and umbilical cord lining banking services in Asia.